Neurotransmitter changes and rewiring of brain circuitry occur in response to prolonged parkinsonism and drug treatment, ultimately leading to abnormalities and LID. Understanding these complex changes in neuronal connections, structures and transmitters has led MentiNova to target an important regulatory system in a unique manner. Identifying an already safe therapeutic for another indication acting on these mechanisms allows us to progress through a repurposing approach. We have proven that this therapeutic is efficacious in the gold standard model of LID making its clinical advancement the next step in development. The approach is scientifically rational, differentiated from other therapeutic concepts, and proven effective.